CLLK.F Stock Overview Operates as a bioconvergence company in North America, Europe, Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BICO Group AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BICO Group Historical stock prices Current Share Price SEK 2.77 52 Week High SEK 6.07 52 Week Low SEK 2.59 Beta 2.38 1 Month Change -7.97% 3 Month Change -32.11% 1 Year Change -55.25% 3 Year Change -90.18% 5 Year Change -92.33% Change since IPO -80.47%
Recent News & Updates
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 29
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 28 BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025
BICO Group AB (publ), Annual General Meeting, May 08, 2025 Oct 09
BICO Group AB Announces Management Changes Jul 10
BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors May 23 See more updates
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 29
Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million. Nov 28 BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025
BICO Group AB (publ), Annual General Meeting, May 08, 2025 Oct 09
BICO Group AB Announces Management Changes Jul 10
BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors May 23
BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024 Apr 19
BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors Apr 16
BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025 Mar 15 BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024
BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR Jan 25 BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024 BICO Group AB (publ) Announces Chief Executive Officer Changes
Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million. Aug 04
BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors May 10
BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024 May 05
BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023 Jan 06
BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO Jan 03
BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023 Nov 22
BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023 Nov 10 BICO Group Announces Appointment of Nomination Committee 2023 BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023
BICO Group Adds Åsa Hillsten as SVP and Head of IR May 12
BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million. May 08
BICO (publ) Appoints Mikael Engblom as Interim CFO May 02 BICO Group AB (Publ) Announces Board Appointments
BICO Reaches Beneficial and Sustainable Solution with Organovo Feb 24
DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022 Feb 03
BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink Jan 12
BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc. Dec 17
BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million. Aug 28
CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures Jul 03
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc. Jul 01
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million. Jun 01 Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.
Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million. Mar 12
Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million. Mar 03 Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022
Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million. Feb 16
Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation Feb 09
Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery Jan 29
Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience Jan 20
Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors Dec 19
CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community Dec 05
CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project Nov 10 Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020
Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit Oct 03
Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders. Sep 05 Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million. Shareholder Returns CLLK.F US Life Sciences US Market 7D -5.5% -1.2% -2.8% 1Y -55.3% -4.2% 24.1%
See full shareholder returns
Return vs Market: CLLK.F underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is CLLK.F's price volatile compared to industry and market? CLLK.F volatility CLLK.F Average Weekly Movement n/a Life Sciences Industry Average Movement 9.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CLLK.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLLK.F's volatility change over the past year.
About the Company BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
Show more BICO Group AB (publ) Fundamentals Summary How do BICO Group's earnings and revenue compare to its market cap? CLLK.F fundamental statistics Market cap US$207.11m Earnings (TTM ) -US$152.73m Revenue (TTM ) US$208.95m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CLLK.F income statement (TTM ) Revenue SEK 2.33b Cost of Revenue SEK 639.40m Gross Profit SEK 1.69b Other Expenses SEK 3.40b Earnings -SEK 1.70b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
Earnings per share (EPS) -24.14 Gross Margin 72.57% Net Profit Margin -73.09% Debt/Equity Ratio 52.8%
How did CLLK.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 13:49 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BICO Group AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dylan van Haaften Bryan Garnier & Co Hanseung Yoo Bryan Garnier & Co Maria Vara Fernández Bryan Garnier & Co
Show 1 more analysts 
